CAPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

CAPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Capricor between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . New York, New York--(Newsfile Corp. - September 7, 2026) - Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) that the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) that, as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) that, as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 27, 2026, before the market opened, the FDA released briefing documents ahead of its AdCom meeting for the BLA, stating that the "benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness." On this news, Capricor's stock fell $12.70, or 64%, to close at $7.00 per share on July 27, 2026, on unusually heavy trading volume. On July 29, 2026, the AdCom met to discuss the Deramiocel BLA, and the panel, in a non-binding 9-3 vote, "concluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy." On this news, Capricor's stock fell $2.38, or 36%, to close at $4.19 per share on July 30, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Capricor's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Capricor class action, go to www.faruqilaw.com/[CAPR](/www.%5BBIO/us/CAPR) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Frequently Asked Questions (FAQ) for Investors Regarding the Capricor Securities Class Action Lawsuit: What is the Capricor securities fraud lawsuit about? The lawsuit alleges that Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its offic...